(Health-NewsWire.Net, October 06, 2017 ) According to Publisher, the Global Blood Screening market is expected to grow from $1.84 billion in 2016 to reach $3.97 billion by 2023 with a CAGR of 11.6%. Growing incidence of infectious diseases, rise in consciousness of donating blood, and increase in health care awareness are some of the factors boosting the market growth. In addition, technological advancements in blood screening techniques, increasing investments in research & development are some of the other factors fuelling the market growth during the forecast period. However, threat from substitute techniques, initial investment costs are some of the restraints limiting the market growth.
For more information http://www.reportsweb.com/blood-screening-global-market-outlook-2017-2023
Blood Screening tests are the foundation of a successful health care system, providing critical information that health care provider and patients need to make the right medical decisions. Blood screening often provide objective, quantitative measurements that inform every stage of care-prevention, detection, diagnosis, treatment, and successful management of health conditions.
North America accounted for the largest share in global blood screening market followed by Europe. Growth of the region is attributed to existence of major companies and developed healthcare infrastructure. Asia Pacific is expected to witness huge growth due to developing economies, raising health care expenditure, and increasing demand for blood screening in emerging countries such as China, Japan and India.
Some of the key players in global blood screening market include Abbott Laboratories, Alere Inc., Apex Biotechnology Corp., Beckman Coulter (A Subsidiary of Danaher Corporation), Becton, Dickinson and Company, Biomérieux, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche, Grifols, Hemosense Inc., Luminex Corp., Nova Biomedical Corp., Ortho Clinical Diagnostics, Inc., Roche Diagnostics, Siemens Healthineers (A Subsidiary of Siemens AG), Thermo Fisher Scientific, Inc., and Trinity Biotech.
Technologies Covered: -Next-generation Sequencing (NGS) -Rapid Tests -Western Blot Assay -Enzyme-Linked Immunosorbent Assay (ELISA) -Nucleic Acid Test (NAT)
Product & Service Types Covered: -Software and Services -Instruments -Reagents & Kits
Applications Covered: -Diabetes Blood Testing -Cardiovascular Disease Blood Testing -Cancer Blood Testing -Blood Disorder Blood Testing -Autoimmune Disease And Food Allergy Testing -Pregnancy Blood Testing -Liver Disorder Blood Testing -Kidney Disorder Blood Testing -Home-Monitoring Blood Testing -Fertility Blood Testing
Request Sample Copy http://www.reportsweb.com/inquiry&RW00011117676/sample
End Users Covered: -Blood Banks -Hospitals
Regions Covered: -North America o US o Canada o Mexico -Europe o Germany o UK o Italy o France o Spain o Rest of Europe -Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific -South America o Argentina o Brazil o Chile o Rest of South America -Middle East & Africa o Saudi Arabia o UAE o Qatar o South Africa o Rest of Middle East & Africa
Make an enquiry: http://www.reportsweb.com/inquiry&RW00011117676/buying
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|